Actualités concernant l’immunothérapie en oncologie pulmonaire

[en] Immunotherapy, based on the immune response to tumor cells, gives a new therapeutic hope for lung cancer whose prognosis remains dark. Four molecules are currently available in clinical practice. They were first studied for non-small cell cancers in the second and third line of treatment with a significant improvement in overall survival, then in maintenance treatment and more recently in the front line with a significant response. Their complications, mainly dysimmune adverse effects, are protean but immunotherapy remains better tolerated than chemotherapy. It opens many perspectives but further studies, including biomarkers, are still needed. © 2018 Editions Medecine et Hygiene. All rights reserved.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

VAILLANT, Frédérique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Canivet, Perrine ; Service de Pneumologie, CHU, Liège, 4000, Belgium

DUYSINX, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Oncologie thoracique

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Language :

French

Title :

Actualités concernant l’immunothérapie en oncologie pulmonaire

Alternative titles :

[en] Insights on immunotherapy in pulmonary oncology

Publication date :

22 August 2018

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Editions Medecine et Hygiene

Volume :

Issue :

615

Pages :

1451-1454

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 October 2019

Statistics

Number of views

94 (22 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359‑86.
Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‑based to a «personalized» approach to cancer staging. CA Cancer J Clin 2017;67:93‑9.
Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823‑59.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next‑generation immunotherapy‑‑inhibiting program‑ med death‑ligand 1 and programmed death‑1. Clin Cancer Res 2012;18:6580‑7.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252‑64.
Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti‑CTLA4 and PD‑1/PD‑L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melano‑ ma and non‑small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:39.
Lantuejoul S, Adam J, Girard N, et al. Tests immunohistochimiques PD‑L1 dans les cancers du poumon non à petites cellules: recommandations par le groupe PATTERN de pathologistes thoraciques. Ann Pathol 2018;38:110‑25.
Reck M, Taylor F, Penrod JR, et al. Impact of nivolumab versus docetaxel on health‑related quality of life and symptoms in patients with advanced squamous non‑small cell lung cancer: results from the CheckMate 017 study. J Thorac Oncol 2018;13:194‑204.
Gralla RJ, Spigel D, Bennett B, et al. PD1.01 (also presented as P2.46): LCSS as a marker of treatment benefit with nivolumab vs docetaxel in pts with advanced non‑squamous NSCLC from Checkmate 057 (abstract). J Thorac Oncol 2016;11:S171.
Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non‑ small‑cell lung cancer: two‑year outcomes from two randomized, open‑label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924‑33.
Novello S, Barlesi F, Califano R, et al. Metastatic non‑small‑cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‑up. Ann Oncol. 2016;27(Suppl.5):v1‑27.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD‑L1‑positive, advanced non‑small‑cell lung cancer (KEYNOTE‑010): a randomised controlled trial. Lancet 2016;387:1540‑50.
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non‑small‑cell lung cancer (POPLAR): a multicentre, open‑label, phase 2 randomised controlled trial. Lancet 2016;387:1837‑46.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non‑small‑cell lung cancer (OAK): a phase 3, open‑label, multicentre randomised controlled trial. Lancet 2017;389:255‑65.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non‑small‑cell lung cancer. N Engl J Med 2017;377:1919‑29.
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11:39‑51.
Brahmer JR, Rodríguez‑Abreu D, Robinson AG, et al. Health‑related quality‑of‑life results for pembrolizumab versus chemotherapy in advanced, PD‑L1‑positive NSCLC (KEYNOTE‑024): a multicentre, international, randomised, open‑label phase 3 trial. Lancet Oncol 2017;18:1600‑9.
Carbone DP, Reck M, Paz‑Ares L, et al. First‑Line nivolumab in stage IV or recurrent non‑small‑cell lung cancer. N Engl J Med 2017;376:2415‑26.
Langer CJ, Obasaju C, Bunn P, et al. Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment. J Thorac Oncol 2016;11:2066‑81.
Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta‑analysis. J Am Acad Dermatol 2013;69:e121‑8.
Mochel MC, Ming ME, Imadojemu S, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol 2016;43:787‑91.
Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti‑PD‑1/PD‑L1 immune checkpoint antibodies. Curr Opin Oncol 2016;28:254‑63.
Pernot S, Ramtohul T, Taieb J. Checkpoint inhibitors and gastrointesti‑ nal immune‑related adverse events. Curr Opin Oncol 2016;28:264‑8.
Gupta A, De Felice KM, Loftus EV, et al. Systematic review: colitis associated with anti‑CTLA‑4 therapy. Aliment Pharmacol Ther 2015;42:406‑17.
Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013;98:1361‑75.
Faje A. Immunotherapy and hypophy‑ sitis: clinical presentation, treatment, and biologic insights. Pituitary 2016;19:82‑92.
Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti‑PD‑1 immunotherapy. Diabetes Care 2015;38:e55‑7.
Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long‑term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020‑30.
Tabchi S, Messier C, Blais N. Immune‑ mediated respiratory adverse events of checkpoint inhibitors. Curr Opin Oncol 2016;28:269‑77.
Makarious D, Horwood K, Coward JIG. Myasthenia gravi s: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 2017;82:128‑36.
Hottinger AF. Neurologic complica‑ tions of immune checkpoint inhibitors. Curr Opin Neurol 2016;29:806‑12.
Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013;31:1071‑7.
Izzedine H, Gueutin V, Gharbi C, et al. Kidney injuries related to ipilimumab. Invest New Drugs 2014;32:769‑73.
Simeone E, Grimaldi AM, Esposito A, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014;8:240.
Chan MMK, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti‑PD1 antibody pembrolizu‑ mab in metastatic melanoma. J Immuno‑ ther 2015;38:37‑9.
Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43‑50.
Martinez‑Calle N, Rodriguez‑Otero P, Villar S, et al. Anti‑PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre‑existing autoimmunity. Haematologi‑ ca 2018;103:e318‑21.
Hanna KS. A rare case of pembrolizu‑ mab‑induced uveitis in a patient with metastatic melanoma. Pharmacother J Hum Pharmacol Drug Ther 2016;36:e183‑8.
de Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 2016;68:556‑7.
Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without embrolizumab for advanced, non‑squamous non‑small‑cell lung cancer: a randomised, phase 2 cohort of the open‑label KEYNOTE‑021 study. Lancet Oncol 2016;17:1497‑08.
Antonia SJ, López‑Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small‑cell lung cancer (CheckMate 032): a multicentre, open‑label, phase 1/2 trial. Lancet Oncol 2016;17:883‑95.
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378:2093‑104.